Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis

ConclusionsThe combination therapy of Zol or DMAb and ELD may increase BMD at 12  months after the first administration in Japanese patients with postmenopausal osteoporosis, regardless of BPs pretreatment. Bone metabolic markers at baseline may be useful predictors for reaction to the therapy and side effects caused by these combination therapies in postmenopausal osteoporosis .
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research